Methodology inspired by publicly taught pipeline-valuation frameworks; all text is an original paraphrase.
Defaults
| Parameter | Default Value | Rationale |
|---|---|---|
| asset_scope | all disclosed assets | Full-pipeline enumeration first |
| pos_source | published phase transition ranges | Starting point, then adjusted with logged reasons |
| status_diff | true | Previous vs current trial status shown per asset |
| competitor_map | true | Same-target and same-indication crowding surfaced |
| value_frame | risk-adjusted | Modeled value = unadjusted peak x POS, both shown |
Preflight
Run canonical pre-flight per contracts/preflight.md. Include the X-Agentii-Trace header on every tool call per contracts/x-agentii-trace-header.md — carry the _run_id from your first tool result and name yourself (and your parent, if you were spawned). Confirm ticker resolution via search_companies before asset queries.
Triggers
- "Analyze [ticker]'s drug pipeline by phase."
- "What are the Phase II and III assets for [ticker]?"
- "Risk-adjust [ticker]'s pipeline with explicit POS assumptions."
- "Which of [ticker]'s programs is most valuable?"
- "What trials recently changed status for [ticker]?"
- "Who else is targeting [mechanism/target]?"
- "How crowded is [indication], and what does that mean for [ticker]?"
- "Log every POS change with reasons for [ticker]'s pipeline."
- "What is the next catalyst for each of [ticker]'s assets?"
- "Compare [ticker]'s pipeline against same-indication competitors."
- "Map [ticker]'s assets by mechanism of action."
- "What does [ticker]'s pipeline say about its runway?"
Production Grounding
- POS discipline: every asset carries an unadjusted peak sales estimate and a phase-appropriate POS; the modeled number is peak x POS, never a bare risk-adjusted figure. Every POS change is logged with its reason (trial data, competitor data, discontinuation) — silent POS drift is a defect.
- Phase ladder: Phase I safety/dosing, Phase II efficacy signal, Phase III registrational; option value rises with phase. Apply scrutiny axes when sizing pivotal assets.
- Status-diff discipline: show previous vs current status per trial (New/Suspended/Terminated/Ahead/Delayed/...); Terminated plus enrollment collapse is a red flag; recruitment-complete starts the readout clock.
- Competitor mapping: same-target and same-indication crowding discounts peak sales, not just POS; mechanism overlap explains class risk.
- Grounding detail lives in
references/knowledge-frameworks.md.
Data Source Priority
get_company_drugs/search_universe_drugs— asset inventory from the med universe.search_drug_knowledge/get_drug_knowledge— mechanism, targets, indications, phase per drug.search_drugs_by_target/search_drugs_by_indication— reverse lookups for the competitor map.search_clinical_trials/get_clinical_trial— status, enrollment, primary-completion dates.search_fda_approvals— registration history;search_earnings_calendarfor timing; knowledge layer viasearch_investment_cases/search_knowledge_entries.
Methodology
Retrieval Scope
structured_only
Retrieval Strategy
- Pull asset inventory (
get_company_drugs), then universe cross-checks (search_universe_drugs). - Enrich per asset from
search_drug_knowledge/get_drug_knowledge(mechanism, targets, phase). - Pull trial records (
search_clinical_trials) for status-diff and next-catalyst dates. - Build the competitor map via
search_drugs_by_target/search_drugs_by_indication. - Size each asset (peak x POS with change log); ground in cases and knowledge entries.
Temporal Scope
See frontmatter temporal_scope block. Development programs span years; status history may reach back 8-12 quarters.
Tool Allowlist
See frontmatter allowed_tools.
Protocol
- Asset enumeration
- Phase and mechanism enrichment
- Status-diff and catalyst dating
- Competitor map assembly
- POS model with change log
Modes
- Phase scan (default): all assets by phase with status-diff and next catalyst.
- POS model: peak x POS modeling with a full change log and scenario brackets.
- Competitor map: target/indication crowding with class-risk read.
Tool Fallbacks
| Failure | Fallback |
|---|---|
| get_company_drugs empty | search_universe_drugs by company or indication; annotate coverage_gap |
| Drug-knowledge record missing | Flag mechanism/competitor data unavailable; never infer targets |
| No trial rows | Mark status undisclosed; note the readout clock is unverified |
| Knowledge tools empty | Proceed with structured data only |
Output File
{ticker}/{YYYY-MM-DD_HHMM}_pipeline-medicines_{affix}.md
Output Structure
- Executive Summary — pipeline stance in 2-3 sentences
- Asset Table — phase, indication, mechanism, status-diff, next catalyst
- POS Model — unadjusted peak, POS, modeled value per asset, change log with reasons
- Competitor Map — same-target and same-indication crowding, class risk
- Historical Context — cases and knowledge entries with /v/ citations
- Coverage Gaps — missing records, undisclosed status, degraded modes
Error Handling
| Error | Fallback |
|---|---|
| Phase unknown | Mark "undisclosed"; do not guess |
| POS source missing | State the assumption range and label it a judgment |
| No catalysts found | Say so explicitly; note the pipeline may be early-stage |
Memory Load
See contracts/memory-load.md.
Snapshot
See contracts/snapshot-synthesis.md.
Final Summary (TUI)
Include ### Key Citations block with 0-10 clickable /v/ URLs.
References
contracts/citation-and-memory.mdcontracts/output-frontmatter-schema.mdcontracts/memory-load.mdcontracts/snapshot-synthesis.mdcontracts/preflight.mdreferences/knowledge-frameworks.md


